Dongwha Pharm announced on the 2nd that its primary axillary hyperhidrosis treatment 'ECCLOCKGel' has been approved by the Ministry of Food and Drug Safety.
Primary axillary hyperhidrosis is a condition characterized by an abnormal amount of sweating in the armpit area without an identifiable cause. Symptoms primarily begin in childhood or adolescence and can lower quality of life due to emotional distress.
Dongwha Pharm signed an exclusive supply contract for ECCLOCKGel with Kaken Pharmaceutical Co. in Japan in June 2023. ECCLOCKGel is a new drug released in Japan that received approval from the Pharmaceuticals and Medical Devices Agency in 2020.
The main ingredient is Sofpironium Bromide. Unlike typical over-the-counter products that use aluminum chloride hydrate to physically block sweat pores, ECCLOCKGel works as an anticholinergic to directly block the signals for sweat secretion at the sweat glands.
This product is designed in a twist form, so when turned once, the amount for one application comes up in the container, allowing for application without getting it on the hands. A representative from Dongwha Pharm noted, "There has been no appropriate treatment option available for hyperhidrosis prescribed as a topical agent in hospitals in Korea," adding, "ECCLOCKGel will change the treatment paradigm for axillary hyperhidrosis."